A Gilead Sciences office environment is demonstrated in Foster Metropolis, California, U.S. May well 1, 2018.
Stephen Lam | Reuters
Gilead Sciences’ experimental drug remdesivir, viewed as a person of the far more promising prospective remedies for the coronavirus, on Monday received the orphan drug designation from the U.S. Foodstuff and Drug Administration.
The announcement arrives days right after U.S. President Donald Trump termed on the Food and drug administration to streamline its approval course of action for solutions these types of as remdesivir, which is currently becoming tested in medical trials, with outcomes envisioned as early as next month.
The orphan drug standing offers a seven-12 months sector exclusivity period of time, as well as tax and other incentives for drug businesses establishing treatments for scarce conditions that have an impact on less than 200,000 people.
Gilead on Sunday said it was briefly putting new emergency access to remdesivir on maintain thanks to an exponential boost in so-referred to as compassionate-use requests for the drug.
There are at present no accredited remedies or preventive vaccines for COVID-19, the ailment prompted by the coronavirus. Most people now get only supportive treatment this kind of as respiration support.